TR200000778T2 - Kısaltılmış yarı-ömüre sahip, tetrazol içeren rapamisin analogları. - Google Patents

Kısaltılmış yarı-ömüre sahip, tetrazol içeren rapamisin analogları.

Info

Publication number
TR200000778T2
TR200000778T2 TR2000/00778T TR200000778T TR200000778T2 TR 200000778 T2 TR200000778 T2 TR 200000778T2 TR 2000/00778 T TR2000/00778 T TR 2000/00778T TR 200000778 T TR200000778 T TR 200000778T TR 200000778 T2 TR200000778 T2 TR 200000778T2
Authority
TR
Turkey
Prior art keywords
immune
life
restenosis
rapamycin analogs
shortened half
Prior art date
Application number
TR2000/00778T
Other languages
English (en)
Inventor
W. Mollison Karl
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000778(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of TR200000778T2 publication Critical patent/TR200000778T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

(Formül (I)). Formül (I) e sahip bir bilesik veya bunun farmasötik açidan kabul edilebilir bir tuzu veya ön-ilaci, bagisiklik ayarlayici (immünomodülatör) bir maddedir ve restenoz, ve immün ve otoimmün hastaliklarinin tedavi edilmesinde yararlidir. Ayrica, kanser, mantar gelisimi, restenoz, nakil sonrasi doku reddedilmesi ve immün ve otoimmün hastaliklari önleyici terkipler ve bunlarin bir memelide, kisaltilmis yari ömürleri sayesinde asgari yan etkilere neden olarak, kanser, mantar gelisimi, restenoz, nakil sonrasi doku reddedilmesi ve immün ve otoimmün hastaliklarinin önlenmesi için kullanimlari açiklanmistir.
TR2000/00778T 1997-09-26 1998-09-24 Kısaltılmış yarı-ömüre sahip, tetrazol içeren rapamisin analogları. TR200000778T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
TR200000778T2 true TR200000778T2 (tr) 2000-07-21

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00778T TR200000778T2 (tr) 1997-09-26 1998-09-24 Kısaltılmış yarı-ömüre sahip, tetrazol içeren rapamisin analogları.

Country Status (27)

Country Link
EP (1) EP1015459B9 (tr)
JP (1) JP3790424B2 (tr)
KR (3) KR100833812B1 (tr)
CN (1) CN1161360C (tr)
AR (1) AR015940A1 (tr)
AT (1) ATE297398T1 (tr)
AU (1) AU745576B2 (tr)
BG (1) BG64955B1 (tr)
BR (1) BR9812305A (tr)
CA (1) CA2303934C (tr)
CO (1) CO5070656A1 (tr)
CZ (1) CZ299365B6 (tr)
DE (1) DE69830502T2 (tr)
DK (1) DK1015459T3 (tr)
ES (1) ES2244087T3 (tr)
HU (1) HU228368B1 (tr)
IL (2) IL134607A0 (tr)
NO (1) NO325813B1 (tr)
NZ (2) NZ502896A (tr)
PL (1) PL191212B1 (tr)
PT (1) PT1015459E (tr)
SI (1) SI1015459T1 (tr)
SK (1) SK285408B6 (tr)
TR (1) TR200000778T2 (tr)
TW (1) TW557297B (tr)
WO (1) WO1999015530A1 (tr)
ZA (1) ZA988750B (tr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE347908T1 (de) * 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
AU2003240714B2 (en) 2002-05-27 2006-09-28 Irm Llc Bis-aromatic alkanols
MXPA05002539A (es) * 2002-09-06 2005-06-17 Abbott Lab Dispositivo medico que tiene inhibidor de hidratacion.
BR0314760A (pt) 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2585840A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
ES2540059T3 (es) 2006-04-26 2015-07-08 Micell Technologies, Inc. Recubrimientos que contienen múltiples fármacos
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
ES2478842T3 (es) 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
KR20160064245A (ko) 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
EP2534152B1 (en) * 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
CN103974938B (zh) 2011-10-14 2016-11-09 百时美施贵宝公司 作为因子xia抑制剂的经取代的四氢异喹啉化合物
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
JP6154473B2 (ja) 2012-10-12 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤の結晶形
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
AU2012395673A1 (en) * 2012-11-30 2014-08-14 Hangzhou Zylox Pharma Co., Ltd. Rapamycin analogs and methods for making same
EP2943253B1 (en) 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2929181A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
NO2760821T3 (tr) 2014-01-31 2018-03-10
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3119425B1 (en) 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3373927A1 (en) 2015-11-11 2018-09-19 Novartis AG Uses of myostatin antagonists, combinations containing them and uses thereof
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3826649A4 (en) 2018-07-23 2022-07-20 Enclear Therapies, Inc. Methods of treating neurological disorders
US12337140B2 (en) 2020-09-29 2025-06-24 Enclear Therapies, Inc. Subarachnoid fluid management method and system with varying rates
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
US20240382628A1 (en) 2021-07-15 2024-11-21 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
WO1998009972A1 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
AU4176897A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Alkylated rapamycin derivatives

Also Published As

Publication number Publication date
CZ299365B6 (cs) 2008-07-02
IL134607A0 (en) 2001-04-30
ES2244087T3 (es) 2005-12-01
PL191212B1 (pl) 2006-03-31
ZA988750B (en) 1999-04-01
EP1015459B9 (en) 2005-10-12
WO1999015530A1 (en) 1999-04-01
HK1030771A1 (en) 2001-05-18
DE69830502D1 (de) 2005-07-14
CN1271361A (zh) 2000-10-25
JP2001517671A (ja) 2001-10-09
DE69830502T2 (de) 2006-05-11
BR9812305A (pt) 2000-09-05
CN1161360C (zh) 2004-08-11
NZ502896A (en) 2001-12-21
EP1015459A1 (en) 2000-07-05
NO325813B1 (no) 2008-07-21
IL134607A (en) 2006-04-10
KR100700319B1 (ko) 2007-03-29
CA2303934A1 (en) 1999-04-01
AU9581998A (en) 1999-04-12
NO20001438D0 (no) 2000-03-20
KR100803639B1 (ko) 2008-02-19
KR100833812B1 (ko) 2008-05-30
SK4172000A3 (en) 2000-08-14
PL339455A1 (en) 2000-12-18
TW557297B (en) 2003-10-11
CA2303934C (en) 2010-01-26
NZ514778A (en) 2005-01-28
HUP0004556A3 (en) 2001-12-28
HU228368B1 (en) 2013-03-28
HUP0004556A2 (hu) 2001-10-28
SK285408B6 (sk) 2007-01-04
BG64955B1 (bg) 2006-10-31
NO20001438L (no) 2000-05-26
CZ20001014A3 (cs) 2000-07-12
SI1015459T1 (en) 2005-10-31
KR20060071092A (ko) 2006-06-26
JP3790424B2 (ja) 2006-06-28
KR20010024298A (ko) 2001-03-26
AR015940A1 (es) 2001-05-30
DK1015459T3 (da) 2005-10-10
PT1015459E (pt) 2005-09-30
EP1015459B1 (en) 2005-06-08
ATE297398T1 (de) 2005-06-15
BG104316A (en) 2000-12-29
KR20070086925A (ko) 2007-08-27
AU745576B2 (en) 2002-03-21
CO5070656A1 (es) 2001-08-28

Similar Documents

Publication Publication Date Title
TR200000778T2 (tr) Kısaltılmış yarı-ömüre sahip, tetrazol içeren rapamisin analogları.
ES2160156T3 (es) Derivados de naftaleno como agonistas de la prostaglandina i2.
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
WO1996016981A3 (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
DE69720773T2 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
DK1142893T3 (da) Substituerede 6(4)-benzyloxypyrimidiner
ATE232520T1 (de) Imidazolidin-4-on derivate verwendbar als antikrebsmittel
TR200100047T2 (tr) Tiyobenzimidazol türevleri
PT1019036E (pt) Utilizacao de d-metionina para reduzir a toxicidade de farmacos ototoxicos e o ruido
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
DK1313697T3 (da) Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
UA49787C2 (uk) Спосіб підвищення цитотоксичності хіміотерапевтичного агента та спосіб підвищення цитотоксичності днк-алкілувального хіміотерапевтичного агента
TR200100075T2 (tr) 2-Kuinolon ihtiva eden farmasötik bileşimler
TR200001690T2 (tr) Triazin damar gelişimi önleyicileri
NZ237884A (en) N-hydroxy-n-linolanyl (chromanyl or quinolinyl) alkyl urea and amide derivatives, preparation and pharmaceutical compositions thereof
TR199801705T2 (tr) Serin proteaz inhibitörleri.
TR199802384T2 (tr) Nörodejeneratif hastaliklarin tedavisinde yararli farmasötik bilesimlerin hazirlanmasi için P-Aminofenol türevlerinin kullanimi.
GR3025207T3 (en) 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents
NO905620D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
TR199801398T2 (tr) Astimi tedavi edici maddeler
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
EP1579872B8 (en) Body weight gain inhibitor
TR199700921T1 (tr) Insanlarda görülen herpes-virüs-8'in tedavisinde pensiklovir'in kullanilmasi.